Recent progress in target therapy in colorectal cancer

Anticancer Research

Volumn 26, Issue 5 B, 2006, Pages 3973-3981

  Pasetto, Lara Maria ^a   Bortolami, Alberto ^a   Falci, Cristina ^a   Sinigaglia, Giulietta ^b   Monfardini, Silvio ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Bevacizumab; Cetuximab; Colorectal cancer; Review

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; IMC 225; IRINOTECAN; OXALIPLATIN; SEMAXANIB; SUNITINIB; VASCULOTROPIN; VATALANIB;

ACNE; ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INHIBITION; FEVER; FOLLICULITIS; GENE TARGETING; HEAD AND NECK CANCER; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LEUKOPENIA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; RASH; REVIEW; SEPSIS; SKIN TOXICITY; THROMBOCYTOPENIA; TOXICITY; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN;

EID: 33750709651     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Guillemard V and Saragovi HU: Novel approaches for targeted cancer therapy. Curr Cancer Drug Targets 4(4): 313-326, 2004.
2. Mendelson J and Baselga J: Status of epidermal growth factor receptor antagonists in biology and treatment of cancer. J Clin Oncol 21: 2787-2799, 2003.
3. Grumwald U and Hidalgo M: Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95: 851-867, 2003.
4. Mendelson J and Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol 33(4): 369-385, 2006.
5. Ng M and Cunningham D: Cetuximab (Erbitux) - an emerging targeted therapy for epidermal growth factor receptor-expressing tumours. Int J Clin Pract 58(10): 970-976, 2004.
6. El-Rayes BF and LoRusso PM: Targeting the epidermal growth factor receptor. Br J Cancer 91(3): 418-424, 2004.
7. Gibson TB, Ranganathan A and Grothey A: Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 6(1): 29-31, 2006.
8. Fukuoka M, Yano S, Giaccone G et al: Multiinstitutional randomised phase II trial of gefinitib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237-2246, 2003.
9. Kris MG, Natale RB, Herbst RS et al: Efficacy of gefinitib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic non-small cell lung cancer: a randomised trial. JAMA 290: 2149-2158, 2003.
10. Giaccone G, Herbst RS, Manegold C et al: Gefinitib in combination with gemcitabine and cisplatin in advanced nonsmall-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22: 777-784, 2004.
11. Herbst RS, Giaccone G, Schiller JH et al: Gefinitib in combination with paclitaxel and carboplatin in advanced nonsmall-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22: 785-794, 2004.
12. Jain RK: Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19(4 Suppl 3): 7-16, 2005.
13. Boige V, Malka D and Ducreux M: Therapeutic strategies using VEGF inhibitors in colorectal cancer. Bull Cancer 92(52): 29-36, 2005.
14. Pisano C, Ottaiano A, Tatangelo F et al: Cyclooxygenase-2 expression is associated with increased size in human sporadic colorectal adenomas. Anticancer Res 25(3B): 2065-2068, 2005.
15. Hurwitz H, Fehrenbacher L, Novotny W et al: Bevacizumab plus irinotecan, fluorouracil and leucovorin for colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
16. Bergsland E and Dickler MN: Maximizing the potential of bevacizumab in cancer treatment. Oncologist 9(Suppl. 1): 36-42, 2004.
17. Haroon Z, Amin K, Saito W, Wilson W, Greenberg CS and Dewhirst MW: SU 5416 delays wound healing trough inhibition of TGF-betal activation. Cancer Biol Ther 1: 121-126, 2002.
18. Buecher B, Bouancheau D and Broquet A et al: Growth inhibitory effect of celecoxib and rofecoxib on human colorectal carcinoma cell lines. Anticancer Res 25(1A): 225-233, 2005.
19. Raymond E, Faivre S, Vera K et al: Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-targeted tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol 22: 192 (abs 769), 2003.
20. Kim DW, Jo YS, Jung HS et al: An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/PTC kinases. J Clin Endocrinol Metab 2006 Jul 18 [Epub ahead of print].
21. Shaheen PE, Rini BI and Bukowski RM: Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports. Clin Genitourin Cancer 5(1): 78-81, 2006.
22. Manning WC, Bello CL, Deprimo SE et al: Pharmacokinetic and pharmacodynamic evaluation of SU11248 in a phase I clinical trial of patients (pts) with imatinib-resistant gastrointestinal stromal tumour (GIST). Proc Am Soc Clin Oncol 22:192 (abs 768), 2003.
23. Gold JS and Dematteo RP: Combined surgical and molecular therapy: the gastrointestinal stromal tumour model. Ann Surg; 244(2): 176-184, 2006.
24. [No authors listed]: Phase III study of Sunitinib malate (su11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 5(1): 23-25, 2006.
25. O'Farrell A-M, Deprimo SE, Manning WC et al: Analysis of biomarkers of SU11248 action in an exploratory study in patients with advanced malignancies. Proc Am Soc Clin Oncol 22: 234 (abs 939), 2003.
26. Toner GC, Mitchell PL, De Boer R et al: PET imaging study of SU11248 in patients with advanced malignancies. Proc Am Soc Clin Oncol 22: 191 (abs 767), 2003.
27. Steward WP, Thomas AL, Morgan B et al: Extended phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK222584 in combination with oxaliplatin/5-fluorouracil (5-FU)/leucovorin as first line treatment for metastatic colorectal cancer. Proc Am Soc Clin Oncol 22: 274 (abs 1098), 2003.
28. Trarbach T, Schleucher N, Riedel U et al: Phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK222584 (PTK/ZK) in combination with irinotecan/5-fluorouracil/leucovorin in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 22: 285 (abs 1144), 2003.
29. George D, Michaelson D, Oh WK et al: Phase I study of PTK787/ZK222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc Am Soc Clin 22: 385 (abs 1548), 2003.
30. Hecht JR, Trarbach T, Jaeger E et al: A randomised, double-blind, placebo-controlled, phase III study in patients (pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK 787/ZK 222584 or placebo (CONFIRM-1), Proc Am Cancer Soc 23: 25 (abs 3), 2005.
31. Minami H, Ebi H, Tahara M et al: A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumours, Proc Am Soc Clin Oncol 22: 194 (abs 778), 2003.
32. Iqbal S and Lenz HJ: Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother Pharmacol 54 Suppl 1: S32-39, 2004.
33. Diasio RB and Fourie J: Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: State of the Art. Drugs 66(11): 1441-1463, 2006.
34. Patiyil S and Alberts SR: Metastatic colorectal cancer: therapeutic options. Curr Treat Options Oncol 7(5): 389-398, 2006.
35. Saltz LB, Meropol NJ, Loehrer PJ Sr, Waksal H, Needle MN, Kopit J and Mayer RJ: Single agent IMC-C225 (Erbitux™) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 21: 127 (abs 504), 2002.
36. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J and Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22(7): 1201-1208, 2004.
37. Saltz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M and LoBuglio A: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20: 3 (abs 7), 2001.
38. Gebbia V, Del Prete S, Borsellino N et al: Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience. Clin Colorectal Cancer 5(6): 422-428, 2006.
39. Cunningham D, Humblet Y, Siena S et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4): 337-345, 2004.
40. Abubakr Y, Eng C, Pautret V et al: Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC). Proc Am Soc Clin Oncol 25: (abs 3556), 2006.
41. Jennis A, Polikoff J, Mitchell E et al: Erbitux (Cetuximab) plus FOLFOX for colorectal cancer (EXPLORE): preliminary efficacy analysis of a randomised phase III trial. Proc Am Soc Clin Oncol 24: (abs 3574), 2005.
42. Van Laethem J-L, Raoul J-L, Mitry E et al: Cetuximab (C225) in combination with bi-weekly irinotecan (CPT-11), infusional 5-fluorouracil (5-FU), and folinic acid (FA) in patients with metastatic colorectal cancer (CRC) expressing the epidermal growth factor receptor (EGFR). Preliminary safety and efficacy results. Proc Am Soc Clin Oncol 22: 264 (abs 1058), 2003.
43. Lang I, Zaluski J, Changchien CR et al: Cetuximab with irinotecan in first-line treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): Preliminary safety results (CRYSTAL). Proc Am Soc Clin Oncol 25: (abs 3555), 2006.
44. Salesi N, Bossone G, Veltri E et al: Clinical experience with bevacizumab in colorectal cancer. Anticancer Res 25(5): 3619-3623, 2005.
45. Chen HX, Mooney M, Boron M et al: Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 24(21): 3354-3360, 2006.
46. Jain RK: Antiangiogenic therapy for cancer: current and emerging concepts. Oncology 19(Suppl. 3): 7-16, 2005.
47. Willet GC, Boucher Y, Di Tomaso E et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145-147, 2004.
48. Giantonio BJ, Levy DE, O'Dwyer PJ, Meropol NJ, Catalano PJ and Benson AB: A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200. Ann Oncol 17(9): 1399-1403, 2006.
49. Saltz LB, Lenz H, Hochster H et al: Randomised phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc Am Soc Clin Oncol 24: (abs 3508), 2005.
50. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al: Phase II, randomised trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21(1): 60-65, 2003.
51. Kabbinavar FF, Schulz J, McCleod M et al: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomised phase II trial. J Clin Oncol 23(16): 3697-3705, 2005.
52. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E and Sarkar S: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23(16): 3660-3662, 2005.
53. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23(15): 3502-3508, 2005.
54. Hochster HS, Hart LL, Ramanathan RK, Hainsworth JD, Hedrick EE and Childs BH: Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. Proc Am Soc Clin Oncol 25: (abs 3510), 2006.
55. Chawla A, Kabbinavar F, Holmgren E et al: Quality of life impact of bevacizumab when combined with irinotecan + 5FU/leucovorin (IFL) and 5FU/leucovorin (FL) for metastatic colorectal cancer. Proc Am Soc Clin Oncol 24: (abs 3564), 2005.
56. Longo R, Sarmiento R, Fanelli M and Gasparini G: Antiangiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 5: 237-256, 2002.
57. Gordon MS, Margolin K, Talpaz M et al: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19: 843-850, 2001.
58. Pasetto LM, Jirillo A, Iadicicco G, Rossi E, Paris MK and Monfardini S: FOLFOX versus FOLFIRI: a comparison of regimens in the treatment of colorectal cancer metastases. Anticancer Res 25(1B): 563-576, 2005.
59. Tirelli U, de Castro Jr G and Awada A: Keynote comment: Reimbursement for molecularly targeted anticancer agents. Lancet 7: 2-3, 2006.